Cannabis is increasingly prescribed clinically and utilized by people living with HIV/AIDS (PLWHA) to address symptoms of HIV disease and to manage side effects of antiretroviral therapy (ART). In light of concerns about the possibly deleterious effect of psychoactive drug use on adherence to ART, we sought to determine the relationship between high-intensity cannabis use and adherence to ART among a community-recruited cohort of HIV-positive illicit drug users. We used data from the ACCESS study, an ongoing prospective cohort study of HIV-seropositive illicit drug users linked to comprehensive ART dispensation records in a setting of universal no-cost HIV care. We estimated the relationship between at least daily cannabis use in the last 6 months, measured longitudinally, and the likelihood of optimal adherence to ART during the same period, using a multivariate linear mixed-effects model accounting for relevant socio-demographic, behavioral, clinical and structural factors. From May 2005 to May 2012, 523 HIV-positive illicit drug users were recruited and contributed 2,430 interviews. At baseline, 121 (23.1 %) participants reported at least daily cannabis use. In bivariate and multivariate analyses we did not observe an association between using cannabis at least daily and optimal adherence to prescribed HAART (Adjusted Odds Ratio = 1.12, 95 % Confidence Interval [95 % CI]: 0.76–1.64, p value = 0.555.) High-intensity cannabis use was not associated with adherence to ART. These findings suggest cannabis may be utilized by PLWHA for medicinal and recreational purposes without compromising effective adherence to ART.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
Tax calculation will be finalised during checkout.
Abrams DI, Hilton JF, Leiser RJ, Shade SB, Elbeik TA, Aweeka FT, Schambelan M. Short-term effects of cannabinoids in patients with HIV-1 infection: a randomized, placebo-controlled clinical trial. Ann Intern Med. 2003;139(4):258.
Abrams DI, Jay CA, Shade SB, Vizoso H, Reda H, Press S, Petersen KL. Cannabis in painful HIV-associated sensory neuropathy: a randomized placebo-controlled trial. Neurology. 2007;68(7):515–21.
Arnsten J, Demas P, Grant R, Gourevitch M, Farzadegan H, Howard A, Schoenbaum E. Impact of active drug use on antiretroviral therapy adherence and viral suppression in HIV-infected drug users. J Gen Intern Med. 2002;17(5):377–81.
Belle-Isle L, Hathaway A. Barriers to access to medical cannabis for canadians living with HIV/AIDS. AIDS Care. 2007;19(4):500–6.
Bonn-Miller MO, Oser ML, Buccosi MB, Trafton JA. (2012) Cannabis use and HIV antiretroviral therapy adherence and HIV-related symptoms. J Behav Med, 12 October 2012. [Epub ahead of print].
Bouhnik AD, Preau M, Vincent E, Carrieri MP, Gallais H, Lepeu G, et al. Depression and clinical progression in HIV-infected DU treated with highly active antiretroviral therapy. Antivir Ther. 2005;10:53–61.
Carrieri MP, Chesney MA, Spire B, Loundou A, Sobel A, Lepeu G, Moatti JP. Failure to maintain adherence to HAART in a cohort of french HIV-positive injecting drug users. Int J Behav Med. 2003;10(1):1–14.
Cescon AM, Cooper C, Chan K, Palmer AK, Klein MB, Machouf N, Loutfy MR, Raboud J, Rachlis A, Ding E, Lima VD, Montaner JSG, Rourke SB, Smieja M, Tsoukas C, Hogg RS. Factors associated with virological suppression among HIV-positive individuals on highly active antiretroviral therapy in a multi-site canadian cohort. HIV Medicine. 2011;12(6):352–60.
Corless IB, Lindgren T, Holzemer W, Robinson L, Moezzi S, Kirksey K, Reynolds N. Marijuana effectiveness as an HIV self-care strategy. Clin Nurs Res. 2009;18(2):172–93.
Crisp BR, Williams M, Timpson S, Ross MW. Medication compliance and satisfaction with treatment for HIV disease in a sample of african-american crack cocaine smokers. AIDS Behav. 2004;8(2):199–206.
Cristiani S, Pukay-Martin N, Bornstein B. Marijuana use and cognitive function in HIV-infected people. J Neuropsychiatry Clin Neurosci. 2004;16(3):330–5.
de Jong B, Prentiss D, McFarland W, Machekano R, Israelski D. Marijuana use and its association with adherence to antiretroviral therapy among HIV-infected persons with moderate to severe nausea. JAIDS. 2005;38(1):43–6.
Department of Justice Canada. (2011). Marihuana medical access regulations. Accessed 12 Sept 2011, from http://lois-laws.justice.gc.ca/eng/regulations/SOR-2001-227/page-1.html.
Ellis RJ, Toperoff W, Vaida F, Van den B Gonzales J, Gouaux B, Atkinson JH. Smoked medicinal cannabis for neuropathic pain in HIV: a randomized, crossover clinical trial. Neuropsychopharmacology. 2009;34(3):672–80.
Fogarty A, Rawstorne P, Prestage G, Crawford J, Grierson J, Kippax S. Marijuana as therapy for people living with HIV/AIDS: social and health aspects. AIDS Care. 2007;19(2):295–301.
Hadland SE, Milloy M-J, Kerr T, Zhang R, Guillemi S, Hogg R, Wood E. Young age predicts poor antiretroviral adherence and viral load suppression among injection drug users. AIDS Patient Care STDs. 2012;26(5):274–80.
Haney M, Gunderson EW, Rabkin J, Hart CL, Vosburg SK, Comer SD, Foltin RW. Dronabinol and marijuana in HIV-positive marijuana smokers: caloric intake, mood, and sleep. JAIDS. 2007;45(5):545–54.
Hinkin CH, Barclay TR, Castellon SA, Levine AJ, Durvasula RS, Marion SD, Longshore D. Drug use and medication adherence among HIV-1 infected individuals. AIDS Behav. 2007;11(2):185–94.
Kerr T, Walsh J, Lloyd-Smith E, Wood E. Measuring adherence to highly active anteretroviral therapy: implications for research and practice. Current HIV/AIDS Report. 2005;2(4):200–5.
Kerr T, Hogg RS, Yip B, Tyndall MW, Montaner J, Wood E. Validity of self-reported adherence among injection drug users. JIAPAC. J Int Assoc Physicians AIDS Care. 2008;7(4):157–9.
Larsen MV, Omland LH, Gerstoft J, Larsen CS, Jensen J, Obel N, Kronborg G. Impact of injecting drug use on mortality in Danish HIV-infected patients: a nation-wide population-based cohort study. Addiction. 2010;105(3):529–35.
Lewden C, Bouteloup V, De Wit S, Sabin C, Mocroft A, Wasmuth JC, van Sighem A, Kirk O, Obel N, Panos G, Ghosn J, Dabis F, Mary-Krause M, Leport C, Perez-Hoyos S, Sobrino-Vegas P, Stephan C, Castagna A, Antinori A, d’Arminio Monforte A, Torti C, Mussini C, Isern V, Calmy A, Teira R, Egger M, Grarup J, Chêne Gl. All-cause mortality in treated HIV-infected adults with CD4 ≥ 500/mm3 compared with the general population: evidence from a large European observational cohort collaboration. Int J Epidemiol. 2012;41(2):433–45.
Low-Beer S, Chan K. Depressive symptoms decline among persons on HIV protease inhibitors. JAIDS. 2000;23(4):295.
Lucas GM, Cheever LW, Chaisson RE, Moore RD. Detrimental effects of continued illicit drug use on the treatment of HIV-1 infection. JAIDS. 2001;27(3):251.
Maldonado G, Greenland S. Simulation study of confounder-selection strategies. Am J Epidemiol. 1993;138(11):923–36.
Malta M, Strathdee SA, Magnanini MMF, Bastos FI. Adherence to antiretroviral therapy for human immunodeficiency virus/acquired immune deficiency syndrome among drug users: a systematic review. Addiction. 2008;103(8):1242–57.
Marshall BD, Kerr T, Shoveller JA, Patterson TL, Buxton JA, Wood E. Homelessness and unstable housing associated with an increased risk of HIV and STI transmission among street-involved youth. Health Place. 2009;15(3):753–60.
May MT, Sterne JAC, Costagliola D, Sabin CA, Phillips AN, Justice AC, Dabis F, Gill J, Lundgren J, Hogg RS, de Wolf F, Fätkenheuer G, Staszewski S, d’Arminio MA, Egger M. HIV treatment response and prognosis in europe and north america in the first decade of highly active antiretroviral therapy: a collaborative analysis. Lancet. 2006;368(9534):451–8.
Milloy MJ, Kerr T, Buxton J, Rhodes T, Guillemi S, Hogg R, Wood E. Dose-response effect of incarceration events on nonadherence to HIV antiretroviral therapy among injection drug users. J Infect Dis. 2011;203(9):1215–21.
Milloy M-J, Kerr T, Bangsberg DR, Buxton J, Parashar S, Guillemi S, Wood E. Homelessness as a structural barrier to effective antiretroviral therapy among HIV-seropositive illicit drug users in a canadian setting. AIDS Patient Care STDs. 2012;26(1):60–7.
Nolan S, Milloy M, Zhang R, Kerr T, Hogg RSG, Wood E. Adherence and plasma HIV RNA response to antiretroviral therapy among HIV-seropositive injection drug users in a canadian setting. AIDS Care. 2011;23(8):980–7.
Obel N, Omland LH, Kronborg G, Larsen CS, Pedersen C, Pedersen G, Sorensen HT, Gerstoft J. Impact of non-HIV and HIV risk factors on survival in HIV-infected patients on HAART: a population-based nationwide cohort study. PLoS ONE. 2011;6(7):e22698.
Palepu A, Tyndall MW, Joy R, Kerr T, Wood E, Press N, Montaner J. Antiretroviral adherence and HIV treatment outcomes among HIV/HCV co-infected injection drug users: the role of methadone maintenance therapy. Drug Alcohol Depend. 2006;84(2):188–94.
Palepu A, Yip B, Miller C, Strathdee SA, O’Shaughnessy MV, Montaner JS, Hogg RS. Factors associated with the response to antiretroviral therapy among HIV-infected patients with and without a history of injection drug use. AIDS. 2001;15(3):423–4.
Palepu A, Milloy M-J, Kerr T, Zhang R, Wood E. Homelessness and adherence to antiretroviral therapy among a cohort of HIV-infected injection drug users. J Urban Health. 2011;88(3):545–55.
Palepu A, Tyndall MW, Chan K, Wood E, Montaner JSG, Hogg RS. Initiating highly active antiretroviral therapy and continuity of HIV care: the impact of incarceration and prison release on adherence and HIV treatment outcomes. Antivir Ther. 2004;9(5):713–9.
Prentiss D, Power R, Balmas G, Tzuang G, Israelski DM. Patterns of marijuana use among patients with HIV/AIDS followed in a public health care setting. JAIDS. 2004;35(1):38–45.
Radloff LS. The CES-D scale: a self-report depression scale for research in the general population. Appl Psychol Meas. 1977;1(3):385–401.
Richardson L, Wood E, Li K, Kerr T. Factors associated with employment among a cohort of injection drug users. Drug Alcohol Rev. 2010;29(3):293–300.
Sangsari S, Milloy MJ, Ibrahim A, Kerr T, Zhang R, Montaner J, and Wood E. Physician experience and rates of plasma HIV-1 RNA suppression among illicit drug users: An observational study. BMC Infect Dis. 2012;12:22.
Sharpe TT, Lee LM, Nakashima AK, Elam-Evans L, Fleming PL. Crack cocaine use and adherence to antiretroviral treatment among HIV-infected black women. J Community Health. 2004;29(2):117–27.
Tapp C, Milloy M, Kerr T, Zhang R, Guillemi S, Hogg RS, Wood E. Female gender predicts lower access and adherence to antiretroviral therapy in a setting of free healthcare. BMC Infect Dis. 2011;11:86.
Ware MA, Rueda S, Singer J, Kilby D. Cannabis use by persons living with HIV/AIDS: patterns and prevalence of use. J Cannabis Ther. 2003;3(2):3–15.
Wilson K, Doxanakis A, Fairley K. Predictors for non-adherence to antiretroviral therapy. Sexual Health. 2004;1(4):251–7.
Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy M, Montaner J. Effect of medication adherence on survival of HIV-infected adults who start highly active antiretroviral therapy when the CD4+ cell count is 0.200 to 0.350 × 10(9) cells/L. Ann Intern Med. 2003;139(10):810.
Wood E, Hogg RS, Lima VD, Kerr T, Yip B, Marshall BDL, Montaner JSG. Highly active antiretroviral therapy and survival in HIV-infected injection drug users. JAMA. 2008;300(5):550–4.
Wood E, Hogg RS, Yip B, Harrigan PR, O’Shaughnessy MV, Montaner JSG. Is there a baseline CD4 cell count that precludes a survival response to modern antiretroviral therapy? AIDS. 2003;17(5):711–20.
Wood E, Montaner JSG, Yip B, Tyndall MW, Schechter MT, O’Shaughnessy MV, Hogg RS. Adherence and plasma HIV RNA responses to highly active antiretroviral therapy among HIV-1 infected injection drug users. CMAJ. 2003;169(7):656–61.
Woolridge E, Barton S, Samuel J, Osorio J, Dougherty A, Holdcroft A. Cannabis use in HIV for pain and other medical symptoms. J Pain Symptom Manage. 2005;29(4):358–67.
Zvolensky MJ, Lewinsohn P, Bernstein A, Schmidt NB, Buckner JD, Seeley J, Bonn-Miller MO. Prospective associations between cannabis use, abuse, and dependence and panic attacks and disorder. J Psychiatr Res. 2008;42(12):1017–23.
Zwahlen M, Harris R, May M, Hogg R, Costagliola D, de Wolf F, Egger M. Mortality of HIV-infected patients starting potent antiretroviral therapy: Comparison with the general population in nine industrialized countries. [Mortality of HIV-infected patients starting potent antiretroviral therapy: comparison with the general population in nine industrialized countries.]. Int J Epidimiol. 2009;38(6):1624–33.
We thank the study participants for their contributions to the research, as well as current and past researchers and staff. We would specifically like to thank Deborah Graham, Tricia Collingham, Carmen Rock, Brandon Marshall, Caitlin Johnston, Steve Kain, Benita Yip, Jennifer Matthews and Kristie Starr for their research and administrative assistance. The study is supported by the US National Institutes of Health (R01-DA021525). This work was supported in part by a Tier 1 Canada Research Chair in Inner-City Medicine awarded to Dr. Wood. Dr. Milloy is supported by the Michael Smith Foundation for Health Research and the Canadian Institutes of Health Research.
About this article
Cite this article
Slawson, G., Milloy, MJ., Balneaves, L. et al. High-Intensity Cannabis Use and Adherence to Antiretroviral Therapy Among People Who Use Illicit Drugs in a Canadian Setting. AIDS Behav 19, 120–127 (2015). https://doi.org/10.1007/s10461-014-0847-3
- Highly-active antiretroviral therapy